Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

is open and Janssen plans to enroll 110 patients worldwide.
  • Phase Ib/II dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive non-Hodgkin's lymphoma. The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP, once a safe dose is established the study will expand and report responses of this combination in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, is open and Janssen plans to enroll 33 patients.
  • Phase II study of ibrutinib in subjects with relapsed or refractory multiple myeloma (MM): This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in subjects with relapsed or relapsed MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. The Company anticipates an update on this study will be provided by year end 2013.
  • Phase II open-label, multicenter, single-arm study of monotherapy ibrutinib in subjects with relapsed or refractory follicular lymphoma. The primary endpoint of this study is objective response rate. Janssen plans to enroll 110 patients in this study.
  • PCYC has received Orphan Drug and Fast Track designation for ibrutinib treatment of chronic lymphocytic leukemia last year. The FDA has also granted Orphan Drug and Fast Track designation most recently to ibrutinib for the treatment of mantle cell lymphoma.  A US orphan drug designation provides the drug developer with several benefits and incentives related to the orphan drug, including a 7-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication. Fast tra
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
    (Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
    (Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
    (Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife Solutions , ... and marketer of proprietary clinical grade hypothermic storage ... shipping products for cells and tissues  ("BioLife" or the ... Meeting of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
    Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
    ... Inc. (OTC Bulletin Board Symbol: CCEL) (the "Company"), ... cord blood banks, today,announced results for fiscal 2007., ... November 30, 2007 were,approximately $17.5 million, up 2% ... November 30, 2006. The Company reported a net ...
    ... 11 AGA Medical Corporation ("AGA"),announced today it received ... ("ADO II"). AGA also announced the immediate availability,and launch ... the AGA family of,occlusion devices designed to occlude or ... heart defect that occurs when a blood vessel,called the ...
    ... Feb. 11 Genta,Incorporated (Nasdaq: GNTA ) ... with institutional investors to sell 6 million shares,of ... proceeds totaling,approximately $3.1 million before fees and expenses. ... about February 13, 2008, subject to the,satisfaction of ...
    Cached Biology Technology:Cryo-Cell International, Inc. Reports Results for Fiscal 2007 2Cryo-Cell International, Inc. Reports Results for Fiscal 2007 3Cryo-Cell International, Inc. Reports Results for Fiscal 2007 4Cryo-Cell International, Inc. Reports Results for Fiscal 2007 5Cryo-Cell International, Inc. Reports Results for Fiscal 2007 6AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II 2Genta Announces Common Stock Offering of Approximately $3.1 Million 2Genta Announces Common Stock Offering of Approximately $3.1 Million 3
    (Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
    (Date:12/24/2014)... 2014  Since its launch in December 2014, the 1U™ ... pain of trying to remember their usernames and passwords through ... their smartphones. To assist people who have struggled to remember ... created 1U and focuses on redefining identity, announced today that ...
    (Date:12/19/2014)... 18, 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... North America Perimeter Security Systems Market" report to their ... The North American perimeter security market is estimated to grow ... the U.S. market holds a larger share in this market, ...
    Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
    ... to know if your child had a fever or ... thoroughly cooked, you would, of course, use a thermometer ... temperature within its range. However, it isn,t that simple ... systemstiny, channel-lined devices used in medical diagnostics, DNA forensics ...
    ... Since most parents in the US are employed, there ... choices for themselves and their children. How parents cope with ... choice coping strategies are the subjects of a study in ... and Behavior . Findings suggest that better work conditions may ...
    ... What about tree power? It turns out that it,s ... in trees for University of Washington researchers to run ... in an upcoming issue of the Institute of ... "As far as we know this is the first ...
    Cached Biology News:NIST calculations may improve temperature measures for microfluidics 2Work conditions impact parents' food choices 2Electrical circuit runs entirely off power in trees 2Electrical circuit runs entirely off power in trees 3